Evelo Biosciences, Inc. (EVLO)

Trade EVLO now with
12/16/2022 6:05:44 AM Evelo Biosciences Announces $45 Mln Loan Agreement With Horizon Technology Finance To Refinance Existing Debt
8/11/2022 6:24:20 AM Evelo Biosciences Q2 Loss Per Share Narrows To $0.40; Says Simba Gill To Transition To Chair
7/18/2022 6:22:44 AM Evelo Biosciences Appoints Marella Thorell As CFO, Effective September 1, 2022
5/25/2022 8:43:19 AM Evelo Biosciences Announces $79.2 Mln Registered Direct Offering Of Common Stock
5/12/2022 6:07:25 AM Evelo Biosciences Q1 Loss Per Share $0.56 Vs Loss $0.55 Last Year
9/27/2021 2:46:19 AM Evelo Biosciences Reports Positive Data From Phase 2 Study Of EDP1815 In Mild And Moderate Psoriasis
9/7/2021 7:12:59 AM Evelo Biosciences Appoints Iain McInnes To Board Of Directors
5/19/2021 9:45:37 AM Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening
4/20/2021 4:07:00 PM Evelo Presents Full Clinical Data From Phase 1b Clinical Trial Cohort Evaluating EDP1815
1/28/2021 9:39:17 PM Evelo Biosciences Prices Underwritten Public Offering Of 4.50 Mln Shares At $15.00/shr
1/20/2021 7:06:43 AM Evelo Biosciences Announces New Positive Confirmatory Data From Phase 1b Trial Of EDP1815 In Atopic Dermatitis